REVTx-99

• REVTx-99 is a nasal solution for the prevention and/or treatment of respiratory viral infection and chronic nasal congestion.

• Sixty seven percent (67%) of subjects in our Phase 1 healthy volunteer study showed a greater than 5-fold increase in IP-10. Three-fold changes in IP-10 have been shown to be protective against influenza and rhinovirus infection in other clinical studies. Additional information can be found in our corporate presentation. 

Background REVTx-99a Phase 1 Study Safety and Biomarker Results REVTx-99a Phase 2 Viral Challenge Study

REVTx-99b Phase 1 Allergen Challenge Study

REVTx-99a Phase 2 Viral Challenge Study

Revelation is conducting a Phase 2 Viral Challenge study with Influenza. This study will evaluate the potential of REVTx-99a to prevent or reduce the severity and duration of infection with influenza. A successful completion of this viral challenge study will de-risk later stage real-world studies required for approval. An outline of the study design and objectives can be found in the corporate presentation.